Physician profile
Shuwei Wang
NPI 1285045211
$2,196.87
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $337 · 2021: $1,177 · 2022: $208 · 2023: $47.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.07 | 2019-2023 | Rinvoq |
| Amgen INC. | $341.52 | 2019-2022 | |
| Janssen Biotech, INC. | $219.30 | 2019-2022 | |
| Pfizer INC. | $160.57 | 2019-2021 | |
| Genentech USA, INC. | $147.60 | 2019-2020 | |
| Ucb, INC. | $127.73 | 2019-2021 | |
| Lilly USA, LLC | $109.69 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $99.43 | 2019-2022 | |
| Genzyme Corporation | $73.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $72.85 | 2020-2022 | |
| Glaxosmithkline, LLC. | $72.41 | 2019-2022 | |
| Horizon Therapeutics Plc | $69.40 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.81 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $51.69 | 2021-2022 | |
| Organon LLC | $42.62 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $29.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.98 | 2021 | |
| Sobi, INC | $27.35 | 2021-2022 | |
| Octapharma USA, INC. | $27.28 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $15.00 | 2021 | |
| Pacira Therapeutics, INC. | $13.43 | 2021 | |
| Radius Health, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuwei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.